Announcing Future Medicinal Chemistry's special issue on antifungal drug discovery
The latest issue looks at challenges and emerging research in antifungal drug discovery
Invasive, life-threatening fungal infections are a significant cause of morbidity and mortality, particularly for patients who have compromised immune function. With only three classes of antifungal agents currently in clinical use and only one class of antifungal drugs approved in the last 30 years, the need for novel therapies is increasingly pressing. This special issue from Future Medicinal Chemistry aims to highlight the work being carried out to address this area of unmet need, from the discovery of new scaffolds and understanding mechanisms of drug resistance to novel antifungal targets.
This issue features an eclectic range of content, including opinion-based papers, primary research and review-style articles, with contributions from Karin Thevissen (KU Leuven, Belgium), Lynette Cegelski (Stanford University, CA, USA) and Terry Roemer (Merk Research Laboratories, NIJ, USA), among many others. Check out the contents of the issue here.